Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of allopurinol--making an old drug safer.

Journal of clinical pharmacology - 1 Jul 2013

Lam May P S, Yeung Chi K, Cheung Bernard M Y

Abstract excerpt

Allopurinol is a drug that has been used for decades to lower serum urate levels in patients with gout or chronic renal failure and in cancer patients undergoing chemotherapy at risk of tumor lysis syndrome. Patients may develop cutaneous hypersensitivity reactions, ranging from mild rashes to potentially fatal severe cutaneous adverse reactions (SCARs) namely drug hypersensitivity syndrome, Stevens-Johnson...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Drug-Related Side Effects and Adverse Reactions
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Pharmacogenetics

Source

Identifiers

PMID: 23381951
DOI: 10.1002/jcph.67

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of allopurinol--making an old drug safer.PMID 23381951Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Semantic proximity Read ↗

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Semantic proximity Read ↗

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Semantic proximity Read ↗

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Semantic proximity Read ↗

Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions.Semantic proximity Read ↗

Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.Semantic proximity Read ↗

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Semantic proximity Read ↗

HLA-B*58:01 is an Incomplete Predictor of Allopurinol-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Semantic proximity Read ↗

Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.Semantic proximity Read ↗

HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy.Semantic proximity Read ↗

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.